QUILT-3.055

A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination with Pembrolizumab or Nivolumab in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer who have Disease Progression Following an Initial Response to Treatment with PD-1 Checkpoint Inhibitor Therapy

What We’ve Been Up to Lately

Our research team was recently awarded with the Gold Certificate of Excellence by the NCI Community Oncology Research Program. This award is given to research teams who are able to enroll a specified number of patients onto NCI sponsored clinical trials within a certain time period. Our team is one of 43 total to have been given this award so far this year. We would not have been able to earn this award without the help of our wonderful patients and is a testament to them!